T89, also known as Dantonic pill, is a botanical product used to treat chronic stable angina pectoris due to coronary heart disease and aims to become the first traditional Chinese medicine to receive FDA approval in the US.
Tasly Pharmaceuticals is conducting two global Phase III trials for the Dantonic pill and ICON has received the 3-arm Phase III clinical trial.
Tasly Pharmaceuticals president Henry Sun said they looked for a company with large global infrastructure supported by advanced regional testing facilities for the Phase III trials.
"In ICON we have found a trusted development partner with all of these attributes and one that also has a strong reputation for delivering quality clinical programs," Sun added.